个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ ESCI

作者：
Chen Hong[1] * ; Wen Yan[2] * ; Zeng Yun[3] * ; Lin Lie[4] * ; Sun Bihong[5] ; Zhu Hongqian[6] ; He Huiqing[7] ; Wang Xiaotao[8] ; Zou Waiyi[9] ; Zheng Caifeng[10] ; Zheng Liling[11] ; Huang Jinxiong[12] ; Pang Liping[13] ; Huang Jixian[14] ; Zhang Yuming[15] ; Lin Haiqing[16] ; Liu Zelin[17] ; Zhu Wanshou[18] ; Wang Qiang[1] ; Zhou Xuan[1] ; Liu Xiaoli[1] ; Qu Hong[19] ; Liu Zhenfang[20] ; Du Xin[21] ; Xu Na[22] ;
机构： [1]Department of Hematology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Da Dao North, Guangzhou, 510515, Guangdong, China. [2]Department of Hematology, Yunnan Hematology Hospital, First People' Hospital of Yunnan, Affiliated Hospital of Kunming University of Science and Technology, Kunming, China. [3]Department of Hematology, First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming, China. [4]Department of Hematology, Hainan General Hospital, Haikou, China. [5]Department of Hematology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. [6]Department of Hematology, Guizhou Provincial People's Hospital, Guiyang, China. [7]Department of Hematology, Zhongshan People's Hospital, Zhongshan, China. [8]Department of Hematology, Guilin Medical University Affiliated Hospital, Guilin, China. [9]Department of Hematology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. [10]Department of Hematology, Shenzhen Bao An People's Hospital, Shenzhen, China. [11]Department of Hematology, The Second People's Hospital of Guangdong Province, Guangzhou, China. [12]Department of Hematology, Liuzhou People's Hospital, Liuzhou, China. [13]Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China. [14]Department of Hematology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China. [15]Department of Hematology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. [16]Department of Hematology, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China. [17]Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China. [18]Department of Hematology, Gaozhou People's Hospital, Gaozhou, China. [19]Department of Hematology, Panyu Central Hospital, Guangzhou, China. [20]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuang Yong Road, Nanning, 530021, Guangxi, China. liuzhenfang@gxmu.edu.cn. [21]Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen University School of Medicine, 3002 Sungang West Road, Futian District, Shenzhen, 518035, China. duxingz@medmail.com.cn. [22]Department of Hematology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Da Dao North, Guangzhou, 510515, Guangdong, China. sprenaa@163.com.
出处：
DOI： 10.1007/s40487-023-00255-2
ISSN：

关键词： Chronic myeloid leukemia Patient Physician Quality of life Discrepancies

摘要：
Chronic myeloid leukemia (CML) is a chronic disease with treatment-free remission (TFR) increasingly regarded as a feasible goal of treatment. However, various factors may influence adherence to international guidelines for CML management. This study aimed to compare the reporting of care between patients with CML and their treating doctors.Parallel patient and physician online surveys were conducted between September 22, 2021, and March 15, 2022, which focused on the perceptions of 1882 adult patients with CML and 305 physicians regarding tyrosine kinase inhibitor (TKI) treatment options, monitoring and toxicities, TFR, and challenges faced.Among the enrolled patients, 69.9% received first-line imatinib treatment, 18.6% received nilotinib, and 4.7% received dasatinib. Among the patients treated with imatinib, 36.7% switched to other TKIs due to imatinib resistance/intolerance (71.1%), exploration of more potent TKIs to achieve TFR (8.9%), and treating physicians' recommendation (14.0%), with a median duration of initial treatment of 14 months [interquartile range (IQR) 6-36]. Most (91.8%) physicians agreed that the breakpoint cluster region-Abelson 1 (BCR::ABL1) transcript level should be assessed every 3 months, but only 42.7% of individuals committed to 3-monthly testing and only 17.8% strictly followed their treating physicians' recommendation. Half of the patients aimed for TFR; however, just 45.2% of physicians considered TFR as one of the top three goals for their patients. The major concern in obtaining TFR was patients' adherence. Fatigue was often distressing for patients with TKIs, while physicians were more concerned about platelet and neutrophil counts. A total of 12% and 20.8% of patients reported moderate/severe anxiety and depression, respectively, while only 53.7% of physicians had concerns about their patients' mental health. During the coronavirus disease 2019 (COVID-19) pandemic, 69.2% of patients reported a reduction in their income. Among these patients, 61.8% maintained their current treatment, while 7.3% switched to cheaper alternatives or discontinued treatment, with over 80% of these patients belonging to the low-income group.Overcoming challenges in patient-physician communication and treatment access is key to improving disease management and quality of life, especially for patients with low income.ClinicalTrials.gov identifier NCT05092048.© 2023. The Author(s).

基金：
This work was supported by the Open Project of Yunnan Blood Disease Clinical Medical Center (2020LCZXKF-XY05); the Key Basic Research Project of Guangzhou City-Basic and the Applied Basic Research Program of Science (202201011781); National Natural Science Foundation of China (82160039, 81700162); Natural Science Foundation of Guangdong Province (2020A1515010409); and Guangzhou Municipal Science and Technology Bureau (201904010488).
语种：
外文
WOS：
PubmedID：
JCR分区：
出版当年[2023]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Hematology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Da Dao North, Guangzhou, 510515, Guangdong, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Chen Hong,Wen Yan,Zeng Yun,et al.Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors[J].ONCOLOGY AND THERAPY.2024,12(1):131-145.doi:10.1007/s40487-023-00255-2.
APA：
Chen Hong,Wen Yan,Zeng Yun,Lin Lie,Sun Bihong...&Xu Na.(2024).Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.ONCOLOGY AND THERAPY,12,(1)
MLA：
Chen Hong,et al."Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors".ONCOLOGY AND THERAPY 12..1(2024):131-145

相关文献

[1]Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia [2]TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway [3]Anticancer Activity and Molecular Mechanism of Momordica cochinchinensis Seed Extract in Chronic Myeloid Leukemia Cells [4]Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. [5]Analysis of factors that influence the quality of sexual life of climacteric women in China [6]慢性粒细胞白血病患者骨髓部分细胞因子的表达及意义 [7]Anticancer Activity and Molecular Mechanism of Momordica cochinchinensis Seed Extract in Chronic Myeloid Leukemia Cells [8]HEALTH-RELATED QUALITY OF LIFE IN CHINESE CHRONIC PROSTATITIS PATIENTS [9]Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase 3, Randomized, Open-label, Multi-center FESTnd Study. [10]LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275

资源点击量：82490 今日访问量：0 总访问量：681 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号